Cinctive Capital Management LP Invests $10.47 Million in Eli Lilly and Company $LLY

Cinctive Capital Management LP bought a new position in shares of Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,746 shares of the company’s stock, valued at approximately $10,474,000.

Several other large investors have also made changes to their positions in the business. Claro Advisors Inc. raised its stake in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Claro Advisors Inc. now owns 3,135 shares of the company’s stock worth $3,369,000 after buying an additional 57 shares during the period. Clay Northam Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $277,000. Concentric Capital Strategies LP raised its stake in shares of Eli Lilly and Company by 4.0% during the 4th quarter. Concentric Capital Strategies LP now owns 848 shares of the company’s stock worth $911,000 after buying an additional 33 shares during the period. City National Bank of Florida MSD raised its stake in shares of Eli Lilly and Company by 18.0% during the 4th quarter. City National Bank of Florida MSD now owns 1,855 shares of the company’s stock worth $1,994,000 after buying an additional 283 shares during the period. Finally, Artia Global Partners LP raised its stake in shares of Eli Lilly and Company by 76.0% during the 4th quarter. Artia Global Partners LP now owns 50,500 shares of the company’s stock worth $54,271,000 after buying an additional 21,800 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 1.0%

Shares of LLY opened at $1,111.43 on Thursday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,182.73. The stock has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 39.48, a PEG ratio of 1.23 and a beta of 0.53. The stock has a 50 day moving average price of $1,009.79 and a 200 day moving average price of $1,016.67.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the business earned $3.34 earnings per share. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on LLY shares. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 8th. Daiwa Securities Group upped their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Finally, Berenberg Bank upped their target price on Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research note on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its neuroscience and pain pipeline by acquiring 4E Therapeutics, a move that could add a non-opioid chronic pain opportunity and diversify growth beyond obesity drugs. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also continues to advance multiple clinical programs, including new studies in Alzheimer’s, neurology, psoriasis, and pain, reinforcing expectations that Lilly can keep building future revenue streams. Lilly Expands Donanemab Ambitions With New Lewy Body Dementia Trial
• Positive Sentiment: Separately, commentary from Jim Cramer urging investors to stay in the stock may have helped sentiment around Lilly’s long-term growth story. Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”
• Neutral Sentiment: Johnson & Johnson’s decision to stay out of obesity drugs is a reminder that Lilly’s blockbuster GLP-1 franchise remains a major competitive advantage, but it does not directly change Lilly’s near-term fundamentals. J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030
• Negative Sentiment: The biggest drag is Lilly’s decision to cut its planned Germany investment in half, citing European drug-pricing reforms that could hurt future R&D and manufacturing economics. That raises concern about international margins and capital allocation. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
• Negative Sentiment: Broader reporting on big pharma pressure tactics in Europe keeps regulatory and pricing risk in focus for Lilly and other drugmakers, which may weigh on investor sentiment if pricing fights escalate. Big pharma taps UK playbook to pressure Europe on drug prices

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.